An interaction between two proteins — one called Rhes and the other Slc4a7 — helps to build tiny tunnels between nerve cells that allow mutant huntingtin protein, the cause of Huntington’s disease, to move from one neuron to another and spread throughout the brain. Those are the findings of…
News
Roflumilast, an oral therapy approved in the U.S. to treat inflammatory lung disease, was shown to reduce brain inflammation, promote the health of connections between brain cells, and ease symptoms in a rat model of Huntington’s disease. According to the research team, from Cairo University in Egypt, these beneficial…
Women with Huntington’s disease are more likely to experience irritability and to be unemployed or working part-time than men with the neurodegenerative condition, according to a small, single-center study in Austria. Men and women with Huntington’s showed similar genetic burden, age at disease onset, and motor symptom severity, suggesting…
The U.S. Food and Drug Administration (FDA) has asked uniQure to conduct an additional clinical trial before submitting an application seeking approval of its experimental gene therapy, AMT-130, for Huntington’s disease. That’s according to a press release from uniQure announcing the final minutes of a Type A…
Combining pridopidine and FA10, two investigational compounds for Huntington’s disease that target different proteins in the brain, was found to protect against nerve cell death better than either treatment alone. That’s according to a new study that used a cellular model of the genetic disorder to assess the…
U.K. biotech company Harness Therapeutics has selected HRN001 as its lead experimental treatment candidate for Huntington’s disease. “The nomination of HRN001 represents a pivotal milestone for Harness and underscores our commitment to the Huntington’s disease community,” Jan Thirkettle, PhD, CEO of Harness, said in a company press…
The New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has given Sarepta Therapeutics the go-ahead to start a first-in-human Phase 1 clinical trial of its investigational therapy SRP-1005 for Huntington’s disease. Sarepta plans to start the trial, dubbed Study SRP-1005-101 or INSIGHTT, between April and June, according to a…
Nine months of treatment with Skyhawk Therapeutics’ oral candidate SKY-0515 appears to have slowed disease progression relative to its natural course in people with early-stage Huntington’s disease. That’s according to new interim data from a substudy, or Part C (ACTRN12624000602527), of an Australia-based Phase 1 clinical trial…
Comedian and actor Will Forte is teaming up with Teva Pharmaceuticals to raise awareness about Huntington’s disease (HD). Forte has signed on as an ambassador for Teva’s Honestly HD campaign, sharing his family’s story with Huntington’s in hopes of offering resources…
Ingrezza (valbenazine) engages with its VMAT2 target more strongly than extended-release Austedo XR (deutetrabenazine), which may translate into better control of chorea by more effectively reducing excess dopamine, the cause of these uncontrolled movements in Huntington’s disease and tardive dyskinesia, according to a study. Both medications are…
Recent Posts
- Learning how to grieve my life before Huntington’s disease
- Proteins in tiny cell tunnels may be Huntington’s treatment target
- What Cuban food taught my wife about rare disease research
- The reality of invisible symptoms and the myth of ‘you don’t look sick’
- Lung disease treatment shown to ease symptoms in Huntington’s rat model